Research
Hormonal
Interval walking (alternating fast and slow speeds) improves glucose effectiveness and insulin sensitivity more effectively than continuous walking of matched energy expenditure in T2DM patients.
If you want to maximize the metabolic benefits of walking, try interval walking. Alternate 1 minute of brisk walking with 1 minute of normal walking for 60 minutes, 5 times a week. This method may improve your insulin sensitivity more than walking at a constant speed.
LimitedSupportsMEDIUM confidence
In this study, as compared with changes in a non-exercise control group, the glucose daily profile... and total and visceral fat... decreased, whereas insulin sensitivity... increased in the interval-walking group. Conversely, all these changes did not reach statistical significance in the continuous walking group.
Why this rating
Based on a small number of studies (Karstoft et al.) with specific protocols.
Source
Walking for subjects with type 2 diabetes: a systematic review and joint AMD/SID/SISMES evidence-based practical guideline
P. Moghetti et al. · Sport Sciences for Health · 2020
DOI 10.1007/s11332-020-00690-y
Meta-analysis · 20 studiesCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Regular supervised walking significantly improves glycemic control (HbA1c) in type 2 diabetes patients, with supervised programs showing statistically significant benefits compared to non-supervised ones.Moderate
- Short bouts of walking used to interrupt prolonged sitting improve glucose profiles in sedentary T2DM patients.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →